Short answer
Assembly Biosciences Inc (ASMB) filed its fiscal 2014 10-K annual report with the SEC on Mar 12, 2015.
- Top risk flagged: FDA approval risk: HBV and microbiome candidates remain preclinical, with no approved products or product revenue
Assembly Biosciences Inc FY2014 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Oral biopharmaceutical model targeting potentially curative therapies for HBV and C. difficile-associated infections
- July 11, 2014 merger with Ventrus created Assembly Biosciences and added the HBV-Cure program
- Strategic repositioning toward HBV core protein allosteric modulators and microbiome-based therapeutics
- 21 employees as of February 28, 2015, supported by consultants and contract research organizations
- Planned first HBV clinical trials in 2016 and first CDAD trial in the first half of 2016
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales since inception
- Net loss $23,788,799; R&D expense $10,716,737, down 28.7% from $15,029,078
- Best program HBV, R&D expense $2,536,378; worst Diltiazem, expense down $9,987,000
- Operating cash outflow $14,973,502; equity financing provided $16,725,946, no buybacks or dividends
- Cash expected to fund operations through at least Q2 2016; additional financing required, with clinical and regulatory risks
Risk Factors
- FDA approval risk: HBV and microbiome candidates remain preclinical, with no approved products or product revenue
- Financing runway risk: current resources expected to fund operations only into the second quarter of 2016
- Manufacturing vulnerability: no internal facilities, requiring third-party contractors for all future formulation and production
- Competitive disruption: emerging HBV treatments could render the company’s CpAM technology noncompetitive
- Founder dependency: loss of scientific founder Adam Zlotnick could materially impair HBV therapy development
Generated from the filing text; verify against the original. How to read a 10-K
Other Assembly Biosciences Inc annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.